NICE’s Highly Specialised Technologies (HST) Programme offers a vital route for bringing ultra-rare disease treatments to patients, but navigating it successfully can be complex.
In this on-demand webinar, hear directly from Sheela Upadhyaya, former lead of NICE’s HST Programme, and Nicolas Touchot, VP International Market Access at Rhythm Pharmaceuticals, as they share first-hand insights from both the HTA and industry perspectives.
Key Topics Covered:
- How the HST pathway differs from a standard NICE appraisal (STA)
- How to plan and prepare effectively to optimise outcomes
- Common pitfalls and success factors in HST submissions
- Practical tips for engaging with NICE effectively
Moderated by Charlie Hewitt, Senior Director at Remap Consulting and former Technical Advisor within NICE’s technology appraisals team, this session provides actionable guidance to help you refine your HST strategy and accelerate access for ultra-rare disease therapies.
Access the webinar by clicking the below image or HERE:
If you have any questions or would like to discuss the topic in more detail, please reach out.
Want to dive deeper? Check out these related articles for more insights: